{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.0","upperLimit":"86.7","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The overall response rate (ORR) was defined as the percentage of participants with the best overall response of stringent complete response (sCR), complete response (CR), near complete response (nCR), very good partial response (VGPR), and partial response (PR) as defined by the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and modified European Group for Blood and Marrow Transplantation (EBMT) criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.","id":"OG000","title":"Phase 2 300 mg 2/7 Schedule"}],"paramType":"NUMBER","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months","title":"Percentage of Participants Who Achieved an Overall Response As Assessed by Investigator During Phase 2","type":"PRIMARY","unitOfMeasure":"percentage of participants"}